medRxiv preprint doi: https://doi.org/10.1101/2020.09.15.20195305; this version posted January 28, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

A type I IFN, prothrombotic hyperinflammatory neutrophil signature is distinct for
COVID-19 ARDS
Leila Reyes1‚Ä†, Manuel A. Sanchez-Garcia1‚Ä†, Tyler Morrison1‚Ä†, Andrew J.M. Howden2‚Ä†, Emily
R. Watts1, Simone Arienti1, Pranvera Sadiku1, Patricia Coelho1, Ananda S. Mirchandani1,
Ailiang Zhang1, David Hope3, Sarah K. Clark3, Jo Singleton3, Shonna Johnston1, Robert
Grecian1, Azin Poon1, Sarah McNamara1, Isla Harper1, Max Head Fourman3, Alejandro J.
Brenes2,4, Shalini Pathak2, Amy Lloyd2, Giovanny Rodriguez Blanco5, Alex von Kriegsheim5,
Bart Ghesquiere6, Wesley Vermaelen6, Camila T. Cologna6, Kevin Dhaliwal1, Nik Hirani1,7,
David H. Dockrell1, Moira K. B. Whyte1, David Griffith3, Doreen A. Cantrell2, Sarah R.
Walmsley1*
‚Ä†Contributed
1Centre

equally to the work

for Inflammation Research, Queen‚Äôs Medical Research Institute, University of

Edinburgh, Edinburgh, UK.
2Division

of Cell Signalling and Immunology, University of Dundee, Dundee, UK.

3Anaesthesia,

Critical Care and Pain, University of Edinburgh, Royal Infirmary of Edinburgh,

Edinburgh UK.
4Centre

for Gene Regulation and Expression, University of Dundee, Dundee, UK.

5

The University of Edinburgh MRC Institute of Genetics and Molecular Medicine, University

of Edinburgh, Edinburgh, UK.
6

Laboratory of Angiogenesis and Vascular Metabolism, Vesalius Research Centre, Leuven,

Belgium.
7NHS

Lothian, Respiratory Medicine, Edinburgh Lung Fibrosis Clinic, Royal Infirmary,

Edinburgh, UK
Corresponding author: Prof. Sarah R. Walmsley, MBChB, PhD. Centre for Inflammation
Research (CIR). The University of Edinburgh Medical School, BioQuarter, Little France
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.15.20195305; this version posted January 28, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

Cres., Edinburgh EH16 4TJ.

Telephone: +44 (0)131 242 6785

E-mail:

sarah.walmsley@ed.ac.uk

Abstract
Acute respiratory distress syndrome (ARDS) is a severe critical condition with a high mortality
that is currently in focus given that it is associated with mortality caused by coronavirus
induced disease 2019 (COVID-19). Neutrophils play a key role in the lung injury characteristic
of non-COVID-19 ARDS and there is also accumulating evidence of neutrophil mediated lung
injury in patients who succumb to infection with SARS-CoV-2. We undertook a functional
proteomic and metabolomic survey of circulating neutrophil populations, comparing patients
with COVID-19 ARDS and non-COVID-19 ARDS to understand the molecular basis of
neutrophil dysregulation.

Expansion of the circulating neutrophil compartment and the

presence of activated low and normal density mature and immature neutrophil populations
occurs in ARDS, irrespective of cause. Release of neutrophil granule proteins, neutrophil
activation of the clotting cascade and upregulation of the Mac-1 platelet binding complex with
formation of neutrophil platelet aggregates is exaggerated in COVID-19 ARDS. Importantly,
activation of components of the neutrophil type I interferon responses is seen in ARDS
following infection with SARS-CoV-2, with associated rewiring of neutrophil metabolism, and
the upregulation of antigen processing and presentation. Whilst dexamethasone treatment
constricts the immature low density neutrophil population it does not impact upon
prothrombotic hyperinflammatory neutrophil signatures.

Keywords Neutrophil, SARS-CoV-2, COVID-19, ARDS, Type I IFN, dexamethasone

medRxiv preprint doi: https://doi.org/10.1101/2020.09.15.20195305; this version posted January 28, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

Summary: Given the crucial role of neutrophils in ARDS and the evidence of a disordered
myeloid response observed in COVID-19 patients, our work maps the molecular basis for
neutrophil reprogramming in the distinct clinical entities of COVID-19 and non-COVID-19
ARDS.

Conclusions: This work maps the molecular basis for neutrophil reprogramming in the distinct
clinical entities of COVID-19 and non-COVID-19 ARDS.

Introduction
Coronavirus disease (COVID-19) is an acute respiratory condition caused by novel coronavirus
(SARS-CoV-2) infection. In the most severe cases (termed ‚ÄúCritical COVID-19‚Äù), infection
with SARS-CoV-2 can lead to the development of acute respiratory distress syndrome (ARDS)
(1). ARDS is a clinical syndrome defined by the presence of bilateral pulmonary infiltrates on
chest radiograph and arterial hypoxaemia that develops acutely in response to a known or
suspected insult. ARDS is known to be the consequence of disordered inflammation (2), and
is characterised by a protein-rich oedema in the alveoli and lung interstitium, driven by
epithelial and vascular injury (2, 3) and increased vascular permeability (4, 5). Limited data
exists regarding the mechanisms causing hypoxaemia and lung inflammation following
infection with SARS-CoV-2, although post-mortem case reports provide evidence of diffuse
alveolar damage, with the presence of proteinaceous exudates in the alveolar spaces, intraalveolar fibrin and alveolar wall expansion (6). In previously described ARDS cohorts in which
SARS-CoV-2 was not an aetiological factor, alveolar damage is associated with worsening
hypoxia and increased mortality (7). In this context, hypoxia is a key driver of dysfunctional

medRxiv preprint doi: https://doi.org/10.1101/2020.09.15.20195305; this version posted January 28, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

inflammation in the lung, augmenting neutrophil persistence and survival (8, 9) and promoting
the release of pro-inflammatory mediators that cause ongoing tissue injury (2, 3). Nondyspnoeic hypoxia is widely described in patients with severe COVID-19 (10), where it is
associated with altered circulating leukocyte profiles with an increase in neutrophil to
lymphocyte ratios and the presence of lymphopaenia (11, 12). More recently, post-mortem
studies have revealed that the diffuse alveolar damage does not directly associate with the
detection of virus, supporting the concept of aberrant host immune responses as drivers of
tissue injury and pulmonary disease progression (13). A disordered myeloid response is further
evidenced by analysis of gene clusters and surface protein expression of whole blood and
peripheral blood mononuclear cell (PBMC) layers of patients with mild and severe COVID-19
(14). However, the functional relevance of these transcriptional signatures remains to be
explored given the limited reliance of neutrophils on transcription to regulate protein
expression (15). It also remains to be addressed whether the observed changes in neutrophil
sub-populations are specific to COVID-19 ARDS or a reflection of the aberrant neutrophil
inflammatory responses more broadly associated with the pathogenesis of ARDS. It is also
unclear as to how these may be impacted by anti-inflammatory strategies including
dexamethasone, which has shown to lower 28-day mortality for patients receiving invasive
mechanical ventilation or oxygen alone (16).

One of the distinct features of COVID-19 that has emerged is the clinical evidence of a prothrombotic state, neutrophil retention within the lung microvasculature and the colocalisation
of neutrophils with platelets in fibrin rich clots (17). Together with evidence of the formation
of neutrophil extracellular traps (NETs) (18, 19) this raises the important question as to whether
neutrophils are inappropriately activated within the circulation thus contributing to vascular
injury and thrombosis in COVID-19. Exploring the differences in neutrophil responses

medRxiv preprint doi: https://doi.org/10.1101/2020.09.15.20195305; this version posted January 28, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

between COVID-19 and non-COVID-19 ARDS provides an opportunity to understand the
mechanisms common to ARDS and those that drive the hypercoagulable hyperinflammatory
state specific to COVID-19 thus identifying urgently required therapeutic targets.

In this program of work, we compared the blood neutrophil populations of patients with
COVID-19 ARDS to those of patients with non-COVID-19 ARDS, moderate COVID-19 and
healthy controls to define the neutrophil host response to SARS-CoV-2. Prior to SARS-CoV2, a significant confounder of ARDS studies has been the heterogeneity of the underlying
processes that result in ARDS with hyperinflammatory and hypoinflammatory phenotypes
described. Infection with SARS-CoV-2 provides a unifying trigger to this aberrant host
response, whilst comparison between COVID-19 and non-COVID-19 ARDS allows us to
identify neutrophil responses that are observed following infection with SARS-CoV-2, or
associated with ARDS all cause.

Methods
Healthy donor and patient recruitment
Human peripheral venous blood was taken from healthy volunteers with written informed
consent obtained from all participants prior to sample collection as approved by the University
of Edinburgh Centre for Inflammation Research Blood Resource Management Committee
(AMREC 15-HV-013). The collection of peripheral venous blood from patients diagnosed with
COVID-19 and/or presenting with ARDS was approved by Scotland A Research Ethics
Committee. Patient recruitment took place from April 2020 through January 2021 from The
Royal Infirmary of Edinburgh, Scotland, UK through the ARDS Neut (20/SS/0002) and
CASCADE (20/SS/0052) Study, with informed consent obtained by proxy. The presence of

medRxiv preprint doi: https://doi.org/10.1101/2020.09.15.20195305; this version posted January 28, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

ARDS was defined using the Berlin criteria (20). Acute physiology and chronic health
evaluation (APACHE II) score = acute physiology score + age points + chronic health points,
was undertaken (minimum score = 0; maximum score = 71), where increasing score is
associated with increasing risk of hospital death (21). Functional Comorbidity Index data (FCI)
was also captured as an 18-item list of comorbidities used to adjust for the effect on
physiological function (22). Scores were performed on intensive care unit admission or earliest
time possible. Infection with SARS-CoV-2 was confirmed by polymerase chain reaction (PCR)
either on nasopharyngeal swab, or deep airway samples. In non-COVID-19 ARDS viral
infection was excluded.

Isolation of human peripheral blood neutrophils
Up to 80 mL of whole blood was collected into citrate tubes. An aliquot of 5 mL of whole
blood was treated with red cell lysis buffer (Invitrogen) and with the remaining volume, human
blood leukocytes were isolated by dextran sedimentation and discontinuous Percoll gradients
as described by Haslett et al. (1985) (23).

Cell Culture
Normal density neutrophils (NDN) obtained from the polymorphonuclear (PMN) layer of
healthy donors were resuspended at 5 √ó 106/mL in Roswell Park Memorial Institute (RPMI)
1640 (Gibco) with 10% dialyzed foetal calf serum (Gibco) and 50 U/mL streptomycin and
penicillin in normoxia (19 kPa) or hypoxia (3 kPa) at 5% CO2 as previously described (24).
Cells were cultured in the absence or presence of interferon (IFN)Œ±/ IFNŒ≤ (500 units/mL)
and/or resiquimod (15 ŒºM, Sigma-Aldrich) for the indicated time prior to harvest. For flow
cytometry studies using dexamethasone and resiquimod, cells were cultured in hypoxia and
pre-treated with varying doses of dexamethasone (0-1 ŒºM) for 4 h, followed by treatment with

medRxiv preprint doi: https://doi.org/10.1101/2020.09.15.20195305; this version posted January 28, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

resiquimod (15 ŒºM) for 1 h. For heavy glutamine tracing studies, NDN were cultured in the
presence of 2 mM U-13C5 glutamine (Cambridge). For extracellular flux analysis, cells were
cultured in the presence or absence of interferon in hypoxia as above before transfer to an
extracellular flux cell culture microplate after 3 hours.

Flow cytometry
Lysed whole blood, PMN and PBMC layers isolated from Percoll gradients, as well as healthy
control NDN used for dexamethasone/resiquimod studies were stained with Zombie Aqua‚Ñ¢
Fixable viability dye (1:400) (Biolegend) to exclude dead cells from analysis. Cells were
subsequently treated with Human TruStain FcX‚Ñ¢ (1:100) (Biolegend) and stained for 30 min
on ice with antibodies listed in Table 1 with appropriate fluorescence minus one (FMO)
controls. Cells were then washed and fixed with 4 % paraformaldehyde (PFA) and acquired
using BD LSRFortessa‚Ñ¢ flow cytometer (Beckton Dickinson). Compensation was performed
using BD FACSDiva‚Ñ¢ software version 8.0 and data analysed in FlowJo version 10.2. Gating
strategy to identify neutrophils, maturity and surface expression of various markers are outlined
in Figure 1. Samples with neutrophil purity of <95% (CD66b+CD49d-) were excluded from
analysis.

Proteomic sample preparation
NDN were centrifuged at 300 √ó g for 5 min at 4 ¬∞C and resuspended in 7 mL of 0.2 % NaCl
(w/v in H2O) for 5 min at room temperature and topped up with 7 mL of 0.2 % NaCl (w/v in
H2O). Cells were washed twice in DPBS (Thermo Fisher), pelleted at 300 √ó g for 5 min at 4
¬∞C and resuspended in 372 ŒºL of freshly made 5% sodium dodecyl sulfate (SDS) lysis buffer
and vortexed. Samples were then heat denatured in a heat block for 5 min at 100 ¬∞C and stored
at ‚Äì80 ¬∞C. Cell lysates were thawed and tris(2-carboxyethyl) phosphine hydrochloride (TCEP)

medRxiv preprint doi: https://doi.org/10.1101/2020.09.15.20195305; this version posted January 28, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

and triethylammonium bicarbonate (TEAB) were added to a final concentration of 10 mM and
50 mM respectively. Lysates were shaken at 500 rpm at 22 ¬∞C for 5 min before being incubated
at 98 ¬∞C for 5 min. Samples were allowed to cool and were then sonicated with a BioRuptor
(30 cycles: 30 s on and 30 s off). Tubes were centrifuged at 17,000 √ó g to collect the cell lysate
and 1 mL of benzonase (27.8 units) was added to each sample and samples incubated at 37 ¬∞C
for 15 min. Samples were then alkylated with addition of 20 mM iodoacetamide for 1 h at 22
¬∞C in the dark. Protein lysates were processed for mass spectrometry using s-trap spin columns
following the manufacturer‚Äôs instructions (Protifi) (25). Lysates were digested with Trypsin at
a ratio 1:20 (protein:enzyme) in 50 mM ammonium bicarbonate. Peptides were eluted from strap columns by sequentially adding 80 mL of 50 mM ammonium bicarbonate followed by 80
mL of 0.2 % formic acid with a final elution using 80 mL of 50 % acetonitrile + 0.2 % formic
acid.

LC-MS analysis
For each sample, 2 mg of peptide was analysed on a Q-Exactive-HF-X (Thermo Scientific)
mass spectrometer coupled with a Dionex Ultimate 3000 RS (Thermo Scientific). LC buffers
were the following: buffer A (0.1% formic acid in Milli-Q water (v/v)) and buffer B (80%
acetonitrile and 0.1% formic acid in Milli-Q water (v/v)). 2 Œºg aliquot of each sample were
loaded at 15 ŒºL/min onto a trap column (100 Œºm √ó 2 cm, PepMap nanoViper C18 column, 5
Œºm, 100 √Ö, Thermo Scientific) equilibrated in 0.1% trifluoroacetic acid (TFA). The trap
column was washed for 3 min at the same flow rate with 0.1% TFA then switched in-line with
a Thermo Scientific, resolving C18 column (75 Œºm √ó 50 cm, PepMap RSLC C18 column, 2
Œºm, 100 √Ö). The peptides were eluted from the column at a constant flow rate of 300 nl/min
with a linear gradient from 3% buffer B to 6% buffer B in 5 min, then from 6% buffer B to
35% buffer B in 115 min, and finally to 80% buffer B within 7 min. The column was then

medRxiv preprint doi: https://doi.org/10.1101/2020.09.15.20195305; this version posted January 28, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

washed with 80% buffer B for 4 min and re-equilibrated in 3% buffer B for 15 min. Two blanks
were run between each sample to reduce carry-over. The column was kept at a constant
temperature of 50 oC at all times.

The data was acquired using an easy spray source operated in positive mode with spray voltage
at 1.9 kV, the capillary temperature at 250 ¬∞C and the funnel RF at 60 ¬∞C. The MS was operated
in DIA mode as reported earlier (26) with some modifications. A scan cycle comprised a full
MS scan (m/z range from 350-1650, with a maximum ion injection time of 20 ms, a resolution
of 120 000 and automatic gain control (AGC) value of 5 √ó 106). MS survey scan was followed
by MS/MS DIA scan events using the following parameters: default charge state of 3,
resolution 30.000, maximum ion injection time 55 ms, AGC 3 x 106, stepped normalized
collision energy 25.5, 27 and 30, fixed first mass 200 m/z. The inclusion list (DIA windows)
and windows widths are shown in Table 2. Data for both MS and MS/MS scans were acquired
in profile mode. Mass accuracy was checked before the start of samples analysis.

Analysis of proteomics data
The DIA data were analyzed with Spectronaut 14 using the directDIA option (27). Cleavage
Rules were set to Trypsin/P, Peptide maximum length was set to 52 amino acids, Peptide
minimum length was set to 7 amino acids and Missed Cleavages set to 2. Calibration Mode
was set to Automatic. Search criteria included carbamidomethylation of cysteine as a fixed
modification, as well as oxidation of methionine, deamidation of asparagine and glutamine and
acetylation (protein N-terminus) as variable modifications. The FDR threshold was set to 1%
Q-value at both the Precursor and Protein level. The single hit definition was to Stripped
sequence. The directDIA data were searched against the human SwissProt database (July 2020)
and included isoforms. The Major Group Quantity was set to the Sum of peptide quantity and

medRxiv preprint doi: https://doi.org/10.1101/2020.09.15.20195305; this version posted January 28, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

the Minor Group Quantity was set to the Sum of the precursor quantity; Cross Run
Normalization was disabled. Fold changes and P-values were calculated in R utilising the
bioconductor package LIMMA version 3.7(28). The Q-values provided were generated in R
using the ‚Äúqvalue‚Äù package version 2.10.0. Estimates of protein copy numbers per cell were
calculated using the histone ruler method (29). The mass of individual proteins was estimated
using the following formula: CN √ó MW/NA = protein mass (g cell‚àí1), where CN is the protein
copy number, MW is the protein molecular weight (in Da) and NA is Avogadro‚Äôs Constant.
Raw mass spectrometry data files and Spectronaut analysis files have been deposited to the
ProteomeXchange (30) Consortium via the PRIDE (31) partner repository.

Cell immunostaining for microscopy
PMN and PBMC layers isolated from Percoll gradients were fixed with 1.5 % PFA. FACS of
NDN and LDN from PMN and PBMC layers respectively were performed using BD
FACSAria‚Ñ¢ Fusion flow cytometer fitted with a 70 ¬µm nozzle and running BD FACSDiva‚Ñ¢
software version 8.0 (Beckton Dickinson). Singlets were gated according to forward scatter
height vs. forward scatter area (FSC-H vs. FSC-A) and side scatter height vs. side scatter area
(SSC-H vs. SSC-A) parameters and NDN and LDN identified according to forward vs. side
scatter (FSC vs. SSC) parameters. NDN and LDN were collected at 4 ¬∞C in 15 mL Falcon tubes
pre-coated with Dulbecco‚Äôs phosphate-buffered saline (DPBS; Thermo Fisher).
Cells were pelleted and blocked with Fc Receptor Blocking Solution followed by staining with
anti-CD41 antibody (Biolegend) and counterstaining with propidium iodide (Biolegend)
according to manufacturer‚Äôs guidelines. Multichamber slides (Ibidi) were used to image the
samples in a confocal microscope (Leica SP8). Image acquisition was performed at 63x
magnification with the same settings across all images. Fiji software was used to process the
images (32). Scale bars depict 5 ÔÅ≠m.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.15.20195305; this version posted January 28, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

Measurement of granule protein levels
Enzyme-linked immunosorbent assay (ELISA) was performed according to manufacturer‚Äôs
protocol to quantify MPO, lactoferrin and elastase levels (Abcam) in plasma from healthy
donors, non-COVID-19 ARDS, COVID-19 patients and cell media supernatant of resiquimod
treated NDN cultures from healthy donors (15 ŒºM, Sigma-Aldrich).

Metabolomic analysis
2.5 √ó 106 neutrophils freshly isolated from the PMN layer of patients were centrifuged at 300
√ó g for 5 min at 4 ¬∞C, with pellets resuspended in 100 ŒºL of 80% methanol. Alternatively, 5 √ó
106 NDN from healthy controls were cultured in hypoxia for 4 h in the presence or absence of
IFNŒ±/IFNŒ≤, washed twice in ice cold saline following culture and lysed in 200 ŒºL of 50:30:20
methanol:acetonitrile:water. Following extraction, samples were stored at ‚Äì80 ¬∞C. Relative
metabolite abundance was determined using ion-pairing Reverse Phase High Performance
Liquid Chromatography (RP-HPLC) or Hydrophilic Interaction Liquid Chromatography
coupled to a Q-exactive Orbitrap Mass Spectrometer. Data were analysed in a targeted manner,
using Xcalibur (Thermofisher Scientific) against an in-house compound library to integrate the
area under the curve at the expected retention time. Individual metabolites were expressed
relative to the mean of the healthy control population and analysed in Prism 9.00 (Graphpad
Software Inc).

Extracellular flux analysis
After culture, cells were harvested into sealed eppendorfs and maintained in hypoxia for one
wash in warm saline. Cells were resuspended at 3 √ó 106/mL in XF DMEM pH 7.4 (Agilent),
supplemented with 2 mM glutamine and IFNŒ±/IFNŒ≤ added to the appropriate cells at the

medRxiv preprint doi: https://doi.org/10.1101/2020.09.15.20195305; this version posted January 28, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

concentrations described previously. 3 √ó 106 neutrophils were adhered into each well of a 24well cell culture microplate (Agilent) pretreated with cell-tak (Corning) to give triplicate
samples per condition with 4 wells were left as media controls. After allowing CO2 to degas
for 45 min in a hypoxic incubator, the plate was loaded into a Seahorse XFe 24 Analyzer
(Agilent) operated in a hypoxic chamber (3% O2, 0.1% CO2; SCI-tive hypoxic work station,
Baker Russkinn). Treatment compounds were resuspended in XF DMEM and cells were
sequentially treated by injection of resiquimod (15ùúáM), glucose (10 mM, Sigma), oligomycin
A (1 ŒºM, Sigma) and 2-deoxyglucose (50 mM, Sigma). All media and compounds were preequilibrated in hypoxia. Data were acquired using Seahorse Wave Controller (version 2.6,
Agilent) and analysed using Wave before exporting to GraphPad to pool for final analysis.

Statistical analyses
Statistical tests were performed using Prism 9.00 software (GraphPad Software Inc). Data was
tested for normality using Shapiro-Wilk test and outliers excluded according to Grubb‚Äôs test,
with significance testing detailed in figure legends. Significance was defined as a p value of
<0.05 after correction for multiple comparisons where applicable. Sample sizes are shown in
figure legends, with each n number representing a different donor.

Results
Study population cohorts
To define the circulating neutrophil response to infection with SARS-CoV-2 we studied
peripheral blood neutrophil populations isolated from hospitalised patients with moderate
COVID-19 and COVID-19 ARDS, comparing these to critical care patients with non-COVID19 ARDS and healthy controls (male, n = 4; female, n = 5; age range: 20 ‚Äì 50 years) (Figure

medRxiv preprint doi: https://doi.org/10.1101/2020.09.15.20195305; this version posted January 28, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

2A). Patient demographic details are provided in Table 3. In accordance with the WHO
COVID-19 classification, patients recruited had either moderate (clinical signs of pneumonia
with oxygen saturations >90%) or critical (ARDS) COVID-19 (33). Patients with Berlin
criteria ARDS had mean APACHE II scores of 18.1 (Non-COVID-19) and 14.8 (COVID-19)
respectively. Viral infections were excluded from the aetiology of non-COVID-19 ARDS. Of
the 12 patients recruited with COVID-19 ARDS, 9 received dexamethasone.

Circulating neutrophil populations are expanded in COVID-19 and non-COVID-19
ARDS
To explore the different neutrophil populations, flow cytometry analysis of whole blood was
first performed to identify CD66b+ cells as neutrophils, with CD16 used as a marker of
maturity. CD66b+CD16+ and CD66b+CD16- cells were observed, indicating the presence of
a heterogenous population of mature and immature neutrophils in ARDS patients, regardless
of COVID-19 status (Figure 2B). Given immature neutrophils are characteristically lowdensity neutrophils (LDN) and associated with disease (34), flow cytometry analysis was
performed on PMN and PBMC layers isolated using Percoll density gradients. Further
characterisation of neutrophil maturity was undertaken by CD10 expression and showed both
a mature (CD66b+CD16+CD10+) and immature (CD66b+CD16-CD10-) LDN population in
the PBMC layer of non-COVID-19 and COVID-19 ARDS patients (Figure 2C). In contrast,
these populations are notably absent in the PBMC layer of healthy control individuals (Figure
2C). Importantly, these LDN populations demonstrated evidence of increased activation states
with loss of CD62L (Figure 2D), and upregulation of both CD66b and CD63 (Figure 2E-F).
Total neutrophil counts generated from Percoll preparations showed a large expansion of
neutrophils in ARDS (Figure 2G). Though a major proportion of the neutrophil population
consisted of mature NDN from the PMN layer, we detected the presence of immature and

medRxiv preprint doi: https://doi.org/10.1101/2020.09.15.20195305; this version posted January 28, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

mature low density neutrophil populations in ARDS patients (Figure 2H). Of note, the increase
in immature LDN in the COVID-19 ARDS cohort was significantly reduced in those receiving
dexamethasone despite a retained expansion of NDN and mature LDN populations (Figure
2H).

Circulating neutrophils restructure their proteomes whilst retaining global cellular
processes in COVID-19 and non-COVID-19 ARDS
A growing body of studies have described a disordered myeloid response following infection
with SARS-CoV-2 using single cell RNA sequencing (scRNA-seq). These studies provide
important insights to the reprogramming of myelopoiesis and the emergence of precursor
neutrophil populations. However, there is a real need to understand how these transcriptional
signatures relate to functional changes in myeloid cell responses, which requires information
at a protein level. To understand changes in the functional proteome of circulating neutrophils
we used a label free Data Independent Acquisition (DIA) mass spectrometry approach.
Estimates of protein copy numbers per cell were calculated using the histone ruler method (29),
along with total cellular protein content and the mass of subcellular compartments. We
compared protein abundance between non-COVID-19 ARDS, COVID-19 ARDS and healthy
control neutrophil populations. Analysis of the NDN populations, common to both healthy
control and ARDS identified around 4500 proteins (Figure 3A), with a subtle reduction in the
total protein content of COVID-19 ARDS neutrophils (Figure 3B). We observed preservation
of global cellular processes across all disease groups evidenced by equivalent mitochondrial
protein content, ribosomal protein content, nuclear envelope protein abundance and
cytoskeletal protein abundance (Figure 3C). Key components of the translation initiation
complex were also conserved across health and disease groups (Figure 3D). This would suggest
that any differences observed in key neutrophil functions are not driven by a loss of core

medRxiv preprint doi: https://doi.org/10.1101/2020.09.15.20195305; this version posted January 28, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

cellular processes and, therefore, more likely to be consequent upon activation of signalling
pathways in response to infectious and inflammatory challenges. Globally we only detected a
small number of proteins involved in transcription factor activity whose abundance was
modified in response to COVID-19 (Figure 3E). These included the interferon regulated
proteins TRIM22 and STAT1, which were induced in COVID-19 ARDS neutrophils and the
glucocorticoid receptor NR3C1 which was down regulated.

To determine which components of the neutrophil proteome remodel in patients with COVID19 and non-COVID-19 ARDS we undertook Linear Models for Microarray data (LIMMA)
analysis to identify significant differences in protein abundance (data are available via
ProteomeXchange). We identified more than 200 proteins to be increased in abundance
between COVID-19 ARDS and healthy control neutrophils which were not significantly
changing in non-COVID ARDS (Figure 4A-B). Gene ontology (GO) term enrichment analysis
of these differentially regulated proteins identified a COVID-19 signature which was defined
by a greater abundance of proteins in type I IFN signalling pathways and the platelet
degranulation (Figure 4B). Change in expression of cullin 2, cyclin dependent kinase 2,
minichromosome maintenance complex

components

(MCM3-5 and MCM7) and

phosphoribosyl pyrophosphate amidotransferase, proteins associated in other cell types with
cell cycle control, was common to both COVID-19 and non-COVID-19 ARDS, whilst proteins
important for mitochondrial translational termination and cell surface receptor signalling
pathways were enriched in non-COVID-19 ARDS samples (Figure 4B). We identified 115
proteins with reduced abundance in ARDS (all cause) versus healthy control neutrophils,
including some proteins that were specific to COVID-19. However, distinct biological
processes impacted by SARS-CoV-2 infection were not identified among those proteins
with reduced abundance.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.15.20195305; this version posted January 28, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

COVID-19 ARDS neutrophils form aggregates with platelets and activate prothrombotic
pathways with enrichment in the low density population
A striking clinical and post-mortem observation in patients with COVID-19 is the prevalence
of micro and macrovascular thrombosis. With previous evidence of NET formation (18, 19),
together with the colocalization of neutrophils with platelets in fibrin rich clots and our
identification of a platelet degranulation signature within the COVID-19 ARDS samples, this
led us to question the mechanism by which neutrophils could be contributing to immune
mediated thrombosis in COVID-19. NDN displayed an overall increase in proteins associated
with fibrin clot formation; fibrinogen alpha, fibrinogen beta and coagulation factor XIII alpha
chain (F13A1) and a failure to induce proteins that inhibit fibrin clot formation in NDN like
antithrombin-III (Figure 5A). This signature was greatest in COVID-19 ARDS neutrophils
(Figure 5A). We also detected a platelet protein signature indicated by the presence of the
platelet proteins platelet factor 4, platelet basic protein (Figure 5B). Confocal imaging on
sorted mature neutrophil populations from COVID-19 ARDS patients subsequently revealed
the existence of a direct physical association between LDN and platelets in these patients, as
opposed to neutrophils from healthy donors (Figure 5C). To understand how neutrophil
platelet aggregates were forming we looked for evidence of platelet activation on the neutrophil
surface, and neutrophil expression of adhesion molecules involved in platelet interactions.
Initial measurements for expression of CD41, a marker of platelet activation, revealed the
presence of CD41 on mature LDN isolated from COVID-19 patients (Figure 5D). This
coincided with a significant increase in mature neutrophil expression of the CD11b component
of the Mac-1 platelet binding complex (Figure 5E). This phenotype was specific to the mature
neutrophil populations, with only low-level surface expression of CD41, CD18, CD11b
observed in the immature LDN population (Figure 5D-E).

medRxiv preprint doi: https://doi.org/10.1101/2020.09.15.20195305; this version posted January 28, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

Toll like receptors (TLRs) are important for viral recognition by the innate immune response.
TLR family members 7 and 8 have been previously reported to enable recognition of single
stranded RNA viruses including influenza and SARS-CoV-2 (35, 36). To directly address
whether neutrophil sensing of SARS-CoV-2 RNA was important for the regulation of Mac-1,
we stimulated healthy control neutrophils with TLR 7 and 8 agonist resiquimod (37).
Additionally, hypoxic culture conditions were used to replicate the systemic hypoxia that
circulating neutrophils are exposed to in patients with COVID-19 ARDS. Resiquimod upregulated neutrophil expression of both components of the Mac-1 platelet binding complex,
CD11b and CD18 (Figure 5F) replicating the observed phenotype of COVID-19. In keeping
with the patient data, the addition of dexamethasone to resiquimod stimulation did not impact
CD11b or CD18 expression (Figure 5F).

The presence of neutrophil platelet aggregates in patients with COVID-19 ARDS led us to
question why neutrophils were binding to activated platelets, and whether there was evidence
that neutrophils themselves were becoming inappropriately activated in the blood. Neutrophils
express a plethora of cell surface receptors to enable them to respond to noxious stimuli. A
key element of this response is the highly regulated release of cytotoxic granule proteins.
However, inappropriate degranulation in the lung tissue during ARDS is associated with
epithelial and vascular damage which in turn potentiates lung injury (38). In health, the release
of toxic granules by neutrophils in the circulation is limited by the requirement of a second
activation stimulus following neutrophil priming (39). Comparison of the proteomes of NDN
populations revealed that granule cargo proteins are highly abundant and account for
approximately 20% of the neutrophil protein mass (Figure 6A). In both COVID-19 and nonCOVID-19 ARDS, whilst we observed an equivalent abundance of primary (CD63, CD68 and

medRxiv preprint doi: https://doi.org/10.1101/2020.09.15.20195305; this version posted January 28, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

Presenilin-1), secondary (Ras related proteins 1A-B and 2A-C), secondary and tertiary
(secretory carrier membrane protein 1-4, vesicle associated membrane protein 2) and
specifically tertiary (solute carrier 11A1) granule membrane proteins (data are available via
ProteomeXchange), there is a relative reduction in the abundance of the granule cargo proteins
within these circulating cells (Figure 6B). Survey of these individual proteases reveals these
changes to be modest, but to occur across the different granule compartments and to be
amplified in COVID-19 (Figure 6C-J). To address whether this relative reduction in intracellular granule protein content was consequent upon neutrophil degranulation, we quantified
surface expression of CD63, a protein known to be externalised upon degranulation, and
CD66b, whose surface expression augments in response to degranulation. We observed a
significant increase in CD63 and CD66b expression which was specific to the COVID-19
ARDS neutrophils (Figure 6K). Importantly an increase in serum levels of the neutrophil
granule proteins myeloperoxidase (MPO), lactoferrin and elastase in the COVID-19 ARDS
patient cohort (Figure 6L) confirmed a phenotype of enhanced circulating neutrophil
degranulation in the COVID-19 ARDS patient cohort, which was not impacted by
dexamethasone (Figure 6M). Consistent with neutrophil sensing of SARS-CoV-2 RNA
promoting activation and degranulation, stimulation of healthy control neutrophils with the
TLR7 and 8 agonist resiquimod increased neutrophil shedding of CD62L and upregulated
expression of CD66b and CD63 (Figure 6N). This resulted in an increase in detectable levels
of the granule proteins MPO and lactoferrin in the cell culture supernatants (Figure 6O).

Activation of neutrophil type I interferon signalling pathways and antigen presentation
in COVID-19
Type I IFN are a group of cytokines which characterise the anti-viral response but are also
implicated in inflammatory disease and in malignancy. Persistent high levels of circulating

medRxiv preprint doi: https://doi.org/10.1101/2020.09.15.20195305; this version posted January 28, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

type I IFN are associated with more severe disease in the late stages of disease (40), thought to
be due to dysfunctional inflammation rather than uncontrolled viral infection. This complexity
is further reflected in the divergent signals in IFN stimulated genes (ISG) described in whole
blood and PBMC myeloid cell populations, where select changes in transcript abundance are
used to identify specific cell clusters (14). Here, we report using LIMMA analysis of NDN
proteomes a type I IFN signature within the COVID-19 ARDS neutrophils (Figure 4B). We
therefore surveyed the abundance of proteins involved in anti-viral responses downstream of
IFNŒ±/Œ≤ receptor (IFNAR). This revealed across the pathway a greater abundance of proteins
important for type I IFN signalling and anti-viral responses in COVID-19 ARDS neutrophils
including 2‚Äô,5‚Äô-oligoadenylate synthetase (OAS) proteins which activate RNase L (Figure 7A),
Eukaryotic Translation Initiation Factor 2-alpha Kinase 2 (EIF2AK) which inhibits viral
transcription (Figure 7B) and the GTP binding Mx proteins which inhibit viral replication
(Figure 7C).

Another important effect of IFN signalling in viral infection is to stimulate antigen presentation
of intracellular (i.e. viral) antigens via the proteosome to alert T-cells to the infected cell.
Analysis of the antigen presentation and processing pathway showed preserved levels of the
immunoproteasome subunits in COVID-19 neutrophils (Figure 7D), but a global increase in
the expression of proteins implicated in immune cell development, regulation, antigen
processing and presentation (Figure 7E). These included a greater copy number of the
Transporter Associated with Antigen Processing (TAP) proteins required for transport into the
endoplasmic reticulum for loading onto class I MHC molecules (Figure 7F), and in class I
MHC molecules themselves (Figure 7G).

medRxiv preprint doi: https://doi.org/10.1101/2020.09.15.20195305; this version posted January 28, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

ARDS neutrophils and type I interferon stimulated healthy neutrophils have altered
metabolic profiles with enhanced glutamine utilisation
Type I IFNs have been found to drive metabolic adaptations in plasmacytoid dendritic cells
(pDC) with upregulation of fatty acid oxidation and oxidative phosphorylation promoting pDC
activation in response to Toll-Like Receptor (TLR) 9 agonists (41). To address whether
neutrophils have the capacity to adapt their metabolic programs in response to type I IFN or
TLR 7 and 8 activation, blood neutrophils from healthy controls were stimulated in the
presence or absence of resiquimod, IFNÔÅ° and IFNÔÅ¢ and glycolysis was assessed by
extracellular flux analysis (Figure 8A). Resiquimod induced a significant uplift in glycolysis
and glycolytic capacity, which was partially abrogated by the addition of type I IFNs (Figure
8A). To further characterise the metabolic rewiring in response to type I IFN we undertook
LC-MS quantification of individual metabolic intermediaries. In keeping with the real time
reduction in extracellular acidification rates, IFN treated neutrophils showed a reduced lactate
content (Figure 8B). This was associated with preservation of TCA cycle intermediaires
including citrate, alphaketoglutarate, malate and succinate (Figure 8C) and a significant
increase in the amino acid glutamate (Figure 8D). Together with (U)-13C5 glutamine tracing
into glutamate this would support the ability of neutrophils to substrate switch in response to
exposure to type I IFN (Figure 8E). To address whether this metabolic rewiring was observed
in blood neutrophils isolated from patients with COVID-19 and non-COVID-19 ARDS we
undertook LC-MS analysis of freshly isolated cells. In contrast to type I IFN stimulation of
healthy control neutrophils, neutrophils from COVID-19 and non-COVID-19 ARDS patients
demonstrated an increase in intracellular levels of free glucose (Figure 8F) while preserving
their lactate content (Figure 8G) and TCA cycle intermediaries (Figure 8H) compared to
healthy control neutrophils, suggesting these cells have equivalent glycolytic flux and TCA
cycle activity. However, in keeping with the capacity of ARDS neutrophils to substrate switch,

medRxiv preprint doi: https://doi.org/10.1101/2020.09.15.20195305; this version posted January 28, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

glutamate levels were elevated in both COVID-19 and non-COVID ARDS neutrophils (Figure
8I).

Discussion
ARDS continues to result in significant mortality despite considerable research endeavour.
The emergence of SARS-CoV-2 infection has confounded this, with 10-20% of hospitalised
patients progressing to ARDS (42). Urgent understanding of the immunological features
specific to COVID-19 ARDS is therefore required. Moreover, the pathophysiological
consequences of myeloid dysfunction as determined by scRNA-seq, mass flow cytometry and
blood count studies is as yet unclear, as is the mechanism by which dexamethasone improves
clinical outcomes in COVID-19 ARDS (14, 40, 43, 44). We therefore employed flow
cytometry and mass spectrometry to characterise disease specific protein and metabolite
signatures in ARDS neutrophil populations and explored their functional implications. Using
this approach, we identify that the expansion of low density and normal density neutrophil
populations previously observed in COVID-19 is also observed in non-COVID-19 ARDS.
Whilst total cell counts are retained in patients receiving dexamethasone therapy, we report an
associated contraction of immature LDN neutrophil populations. It will be important to
understand moving forwards whether a key therapeutic effect of dexamethasone is the
suppression of acute myelopoiesis in response to infection with SARS-CoV-2.

Proteomic survey also allowed us to highlight key processes, including activation of type I IFN
responses that are distinct to COVID-19 ARDS, but more notably, processes not previously
detected by scRNA-seq including platelet degranulation and the expression of proteins
implicated in immune cell development, regulation, antigen processing and presentation.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.15.20195305; this version posted January 28, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

Importantly, these protein signatures were observed within mature NDN, suggesting this not
to be a consequence of disordered myelopoiesis. It is interesting to note that MCM proteins,
that are responsible for the separation of DNA and as such are conventionally associated with
DNA replication, were enriched in both COVID-19 ARDS and non-COVID-19 ARDS. In the
context of neutrophils, a terminally differentiated cell, this may hint to processes involved in
the unravelling of DNA for NET formation rather than cell cycle control and serves as an
interesting concept for further exploration.

A striking clinical divergence between COVID-19 and non-COVID-19 ARDS is the
prominence of micro and macrovascular thrombosis in COVID-19 ARDS. Here, we report
proteomic signatures indicative of platelet degranulation and clotting cascade activation. These
observations together with evidence of neutrophil platelet binding, extend the previously
reported contribution of neutrophils to the pathogenesis of immune clot formation through the
release of NETs to one of TLR mediated neutrophil activation and the formation of neutrophil
platelet aggregates. It is interesting to note that it is the neutrophils within the low density layer
we observe by confocal microscopy to bind to platelets and to be associated with the
upregulating the Mac-1 platelet binding complex in COVID-19 ARDS. Further work will be
required to understand whether LDN also demonstrate a propensity for NETs formation, and
whether these aggregates, previously reported in the lung tissue at post-mortem, impair
neutrophil transmigration and directly contribute to vascular damage and to the formation of
microthrombi (17-19). It will also be important to dissect whether the uplift in expression of
proteins associated with fibrin clot formation in COVID-19 ARDS is consequent upon intrinsic
neutrophil expression of these proteins, neutrophil processing of platelet proteins or reflective
of adherent platelets contributing to the protein signatures of the circulating neutrophil
populations.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.15.20195305; this version posted January 28, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

The importance of neutrophil activation of type I IFN signalling pathways in COVID-19 ARDS
also requires further consideration given the disconnect between tissue injury and viral
detection (45). The ability of neutrophils to cross-present exogenous antigens to CD8+ T cells
has previously been reported and is highly relevant for T cell priming in vivo (46). This may
be particularly relevant in a disease where early CD4+ and CD8+ T cell responses against
SARS-CoV-2 are thought to be protective (47, 48), but late responses are associated with
damaging inflammation (48-51). Whilst activation of anti-viral responses including class I
MHC antigen presentation would therefore appear beneficial with respect to viral control, if
this is associated with a hyper-inflammatory neutrophil phenotype and delayed T cell
activation, the net consequence could be persistent tissue injury. In this regard, we would
predict that inappropriate degranulation of neutrophils in the circulation would be highly
damaging and cause wide-spread inflammation within the microvasculature where neutrophils
are known to be sequestered. Our evidence of expanded neutrophil numbers together with
increased neutrophil activation and degranulation confirmed by the detection of plasma
neutrophil granule proteins in patients with COVID-19 ARDS and TLR-agonist in vitro assays
would support this concept of a hyper-inflammatory, damaging circulating innate response.
These pro-thrombotic hyperinflammatory neutrophil protein signatures would appear to be
retained in patients with COVID-19 ARDS receiving dexamethasone therapy. This is perhaps
not surprising given the paucity of evidence for the impact of corticosteroids on neutrophilic
inflammation, highlighting the need for additional therapeutic strategies.

Finally, the mechanism by which type I IFN regulates neutrophil behaviour remains to be fully
elucidated. In pDC, TLR 9 mediated activation is dependent upon autocrine production of type
I IFNs and an increase in oxidative metabolism (41). Neutrophils are unique in their reliance

medRxiv preprint doi: https://doi.org/10.1101/2020.09.15.20195305; this version posted January 28, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

on non-oxidative metabolism for ATP production, even when oxygen is freely available. It is
therefore of interest that in response to IFNÔÅ° and IFNÔÅ¢, neutrophils rewire their metabolic
programme by reducing their glycolytic potential. Together with an increase in detectable
levels of glutamate in neutrophils isolated from patients with COVID-19 ARDS, and existing
evidence that neutrophils can undergo gluconeogenesis (52), this raises the interesting
possibility that ARDS neutrophils re-wire their metabolic processes to facilitate ongoing
inflammatory responses which may be detrimental to the host. Future work will be required to
better understand whether these metabolic changes potentiate anti-viral and pro-inflammatory
innate immune responses following viral challenge. Of interest small molecules already exist
for targeting glutamine utilisation and have been trialled in the cancer setting, raising the
possibility of metabolic drug repurposing for the treatment of COVID-19 (53).

In summary, using mass spectrometry we describe pathophysiological protein and metabolic
neutrophil signatures that are common to ARDS and those distinct to COVID-19 ARDS. We
identify a type I IFN response in COVID-19 ARDS neutrophils which is associated with
metabolic rewiring, neutrophil degranulation and the formation of neutrophil platelet
aggregates in the blood which persist irrespective of dexamethasone treatment. A clear
limitation of this study is the relatively small number of patients recruited. This is balanced
against the detailed analysis we have been able to perform in these patient groups and the move
towards functional dissection of neutrophil responses not previously captured in transcriptional
data sets.

Further understanding of the mechanisms which regulate aberrant neutrophil

responses will likely be important in developing strategies to target the innate responses
following infection with SARS-CoV-2 to enable an effective therapeutic arsenal for COVID19 ARDS.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.15.20195305; this version posted January 28, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

Author Contributions
L.R, M.A.S.G, T.M, A.J.M.H, E.R.W, S.A, P.S, P.C, A.S.M, A.Z, D.H, S.K.C, J.S, S.J, R.G,
A.P, S.M, I.H, M.H.F, A.B, S.P, A.L, G.R.B, B.G, W.V, C.T.C performed the research. L.R,
M.A.S.G, T.M, A.J.M.H, M.K.W, D.G, D.A.C, S.R.W interpreted the data. L.R, M.A.S.G,
T.M, A.J.M.H, M.H.F, K.D, N.H, D.D, M.K.W, D.G, D.A.C, S.R.W designed the research.
L.R, M.A.S.G, T.M, A.J.M.H, E.R.W, A.K., M.K.W, D.G, D.A.C, S.R.W provided expertise
and feedback. L.R, M.A.S.G, T.M, A.J.M.H, E.R.W, D.A.C, S.R.W wrote the manuscript.

Declaration of Interests
The authors declare no competing interests.

Grant Information
This research was supported by a Wellcome Trust Senior Clinical Fellowship award (209220)
and a CRUK cancer immunology project award (C62207/A24495) to S.R.W, Wellcome
Clinical training Fellowship awards to T.M. (214383/Z/18/Z) and E.R.W (108717/Z/15/Z), a
Wellcome Trust Post-doctoral Training Clinical Fellowship awarded to A.S.M (110086), a
Medical Research Foundation PhD Studentship to S.A., UKRI/NIHR funding through the UK
Coronavirus Immunology Consortium (UK-CIC) and a CSO grant (COV/DUN/20/01) to
D.A.C, and a LifeArc STOPCOVID award to A.P and S.M.

Acknowledgements

medRxiv preprint doi: https://doi.org/10.1101/2020.09.15.20195305; this version posted January 28, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

We thank the CIR blood resource (AMREC no. 15-HV-013) for the recruitment of blood from
healthy donors and the clinical support teams, patients and their families who have contributed
to this study. Many thanks to the QMRI Flow Cytometry & Cell Sorting Facility, Edinburgh
University (Will Ramsay and Mari Pattison) and CALM Facility, Edinburgh University (Rolly
Wiegand and Kseniya Korobchevskaya) for their expertise and assistance.

References
1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu
T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J,
Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected
with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497-506.
2. Acute Respiratory Distress Syndrome Network, Brower RG, Matthay MA, Morris A,
Schoenfeld D, Thompson BT, Wheeler A. Ventilation with lower tidal volumes as
compared with traditional tidal volumes for acute lung injury and the acute respiratory
distress syndrome. N Engl J Med 2000; 342: 1301-1308.
3. Dreyfuss D, Saumon G. Role of tidal volume, FRC, and end-inspiratory volume in the
development of pulmonary edema following mechanical ventilation. Am Rev Respir
Dis 1993; 148: 1194-1203.
4. Bachofen M, Weibel ER. Alterations of the gas exchange apparatus in adult respiratory
insufficiency associated with septicemia. Am Rev Respir Dis 1977; 116: 589-615.
5. Flick MR, Perel A, Staub NC. Leukocytes are required for increased lung microvascular
permeability after microembolization in sheep. Circ Res 1981; 48: 344-351.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.15.20195305; this version posted January 28, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

6. Tian S, Xiong Y, Liu H, Niu L, Guo J, Liao M, Xiao SY. Pathological study of the 2019
novel coronavirus disease (COVID-19) through postmortem core biopsies. Mod
Pathol 2020; 33: 1007-1014.
7. Sharp C, Millar AB, Medford AR. Advances in understanding of the pathogenesis of acute
respiratory distress syndrome. Respiration 2015; 89: 420-434.
8. Eltzschig HK, Carmeliet P. Hypoxia and inflammation. N Engl J Med 2011; 364: 656-665.
9. Walmsley SR, Print C, Farahi N, Peyssonnaux C, Johnson RS, Cramer T, Sobolewski A,
Condliffe AM, Cowburn AS, Johnson N, Chilvers ER. Hypoxia-induced neutrophil
survival is mediated by HIF-1alpha-dependent NF-kappaB activity. J Exp Med 2005;
201: 105-115.
10. Tobin MJ. Basing Respiratory Management of COVID-19 on Physiological Principles.
Am J Respir Crit Care Med 2020; 201: 1319-1320.
11. Liu J, Liu Y, Xiang P, Pu L, Xiong H, Li C, Zhang M, Tan J, Xu Y, Song R, Song M,
Wang L, Zhang W, Han B, Yang L, Wang X, Zhou G, Zhang T, Li B, Wang Y, Chen
Z, Wang X. Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019
coronavirus disease in the early stage. J Transl Med 2020; 18: 206.
12. Zhao Q, Meng M, Kumar R, Wu Y, Huang J, Deng Y, Weng Z, Yang L. Lymphopenia is
associated with severe coronavirus disease 2019 (COVID-19) infections: A systemic
review and meta-analysis. Int J Infect Dis 2020; 96: 131-135.
13. Dorward DA, Russell CD, Um IH, Elshani M, Armstrong SD, Penrice-Randal R, Millar
T, Lerpiniere CEB, Tagliavini G, Hartley CS, Randle NP, Gachanja NN, Potey PMD,
Dong X, Anderson AM, Campbell VL, Duguid AJ, Al Qsous W, BouHaidar R,
Baillie JK, Dhaliwal K, Wallace WA, Bellamy COC, Prost S, Smith C, Hiscox JA,
Harrison DJ, Lucas CD. Tissue-Specific Immunopathology in Fatal COVID-19. Am J
Respir Crit Care Med 2021; 203: 192-201.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.15.20195305; this version posted January 28, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

14. Schulte-Schrepping J, Reusch N, Paclik D, Bassler K, Schlickeiser S, Zhang B, Kramer
B, Krammer T, Brumhard S, Bonaguro L, De Domenico E, Wendisch D, Grasshoff
M, Kapellos TS, Beckstette M, Pecht T, Saglam A, Dietrich O, Mei HE, Schulz AR,
Conrad C, Kunkel D, Vafadarnejad E, Xu CJ, Horne A, Herbert M, Drews A,
Thibeault C, Pfeiffer M, Hippenstiel S, Hocke A, Muller-Redetzky H, Heim KM,
Machleidt F, Uhrig A, Bosquillon de Jarcy L, Jurgens L, Stegemann M, Glosenkamp
CR, Volk HD, Goffinet C, Landthaler M, Wyler E, Georg P, Schneider M, DangHeine C, Neuwinger N, Kappert K, Tauber R, Corman V, Raabe J, Kaiser KM, Vinh
MT, Rieke G, Meisel C, Ulas T, Becker M, Geffers R, Witzenrath M, Drosten C,
Suttorp N, von Kalle C, Kurth F, Handler K, Schultze JL, Aschenbrenner AC, Li Y,
Nattermann J, Sawitzki B, Saliba AE, Sander LE, Deutsche C-OI. Severe COVID-19
Is Marked by a Dysregulated Myeloid Cell Compartment. Cell 2020.
15. Yang P, Li Y, Xie Y, Liu Y. Different Faces for Different Places: Heterogeneity of
Neutrophil Phenotype and Function. J Immunol Res 2019; 2019: 8016254.
16. Group RC, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N,
Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D,
Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan
K, Juszczak E, Baillie JK, Haynes R, Landray MJ. Dexamethasone in Hospitalized
Patients with Covid-19 - Preliminary Report. N Engl J Med 2020.
17. Nicolai L, Leunig A, Brambs S, Kaiser R, Weinberger T, Weigand M, Muenchhoff M,
Hellmuth JC, Ledderose S, Schulz H, Scherer C, Rudelius M, Zoller M, Hochter D,
Keppler O, Teupser D, Zwissler B, Bergwelt-Baildon M, Kaab S, Massberg S,
Pekayvaz K, Stark K. Immunothrombotic Dysregulation in COVID-19 Pneumonia is
Associated with Respiratory Failure and Coagulopathy. Circulation 2020.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.15.20195305; this version posted January 28, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

18. Radermecker C, Detrembleur N, Guiot J, Cavalier E, Henket M, d‚ÄôEmal C, Vanwinge C,
Cataldo D, Oury C, Delvenne P, Marichal T. Neutrophil extracellular traps infiltrate
the lung airway, interstitial, and vascular compartments in severe COVID-19. Journal
of Experimental Medicine 2020; 217.
19. Veras FP, Pontelli MC, Silva CM, Toller-Kawahisa JE, de Lima M, Nascimento DC,
Schneider AH, Caetit√© D, Tavares LA, Paiva IM, Rosales R, Col√≥n D, Martins R,
Castro IA, Almeida GM, Lopes MIF, Benatti MN, Bonjorno LP, Giannini MC,
Luppino-Assad R, Almeida SL, Vilar F, Santana R, Bollela VR, Auxiliadora-Martins
M, Borges M, Miranda CH, Pazin-Filho A, da Silva LLP, Cunha L, Zamboni DS,
Dal-Pizzol F, Leiria LO, Siyuan L, Batah S, Fabro A, Mauad T, Dolhnikoff M,
Duarte-Neto A, Saldiva P, Cunha TM, Alves-Filho JC, Arruda E, Louzada-Junior P,
Oliveira RD, Cunha FQ. SARS-CoV-2‚Äìtriggered neutrophil extracellular traps
mediate COVID-19 pathology. Journal of Experimental Medicine 2020; 217.
20. ARDS Defence Task Force, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND,
Caldwell E, Fan E, Camporota L, Slutsky AS. Acute respiratory distress syndrome:
the Berlin Definition. JAMA 2012; 307: 2526-2533.
21. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease
classification system. Crit Care Med 1985; 13: 818-829.
22. Groll DL, To T, Bombardier C, Wright JG. The development of a comorbidity index with
physical function as the outcome. J Clin Epidemiol 2005; 58: 595-602.
23. Haslett C, Guthrie LA, Kopaniak MM, Johnston RB, Jr., Henson PM. Modulation of
multiple neutrophil functions by preparative methods or trace concentrations of
bacterial lipopolysaccharide. Am J Pathol 1985; 119: 101-110.
24. Walmsley SR, Chilvers ER, Thompson AA, Vaughan K, Marriott HM, Parker LC, Shaw
G, Parmar S, Schneider M, Sabroe I, Dockrell DH, Milo M, Taylor CT, Johnson RS,

medRxiv preprint doi: https://doi.org/10.1101/2020.09.15.20195305; this version posted January 28, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

Pugh CW, Ratcliffe PJ, Maxwell PH, Carmeliet P, Whyte MK. Prolyl hydroxylase 3
(PHD3) is essential for hypoxic regulation of neutrophilic inflammation in humans
and mice. J Clin Invest 2011; 121: 1053-1063.
25. HaileMariam M, Eguez RV, Singh H, Bekele S, Ameni G, Pieper R, Yu Y. S-Trap, an
Ultrafast Sample-Preparation Approach for Shotgun Proteomics. J Proteome Res
2018; 17: 2917-2924.
26. Muntel J, Gandhi T, Verbeke L, Bernhardt OM, Treiber T, Bruderer R, Reiter L.
Surpassing 10 000 identified and quantified proteins in a single run by optimizing
current LC-MS instrumentation and data analysis strategy. Mol Omics 2019; 15: 348360.
27. Bruderer R, Bernhardt OM, Gandhi T, Miladinovic SM, Cheng LY, Messner S,
Ehrenberger T, Zanotelli V, Butscheid Y, Escher C, Vitek O, Rinner O, Reiter L.
Extending the limits of quantitative proteome profiling with data-independent
acquisition and application to acetaminophen-treated three-dimensional liver
microtissues. Mol Cell Proteomics 2015; 14: 1400-1410.
28. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. limma powers
differential expression analyses for RNA-sequencing and microarray studies. Nucleic
Acids Res 2015; 43: e47.
29. Wisniewski JR, Hein MY, Cox J, Mann M. A "proteomic ruler" for protein copy number
and concentration estimation without spike-in standards. Mol Cell Proteomics 2014;
13: 3497-3506.
30. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S,
Rueden C, Saalfeld S, Schmid B, Tinevez JY, White DJ, Hartenstein V, Eliceiri K,
Tomancak P, Cardona A. Fiji: an open-source platform for biological-image analysis.
Nat Methods 2012; 9: 676-682.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.15.20195305; this version posted January 28, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

31. WHO. Clinical management of COVID-19: interim guidance. WHO Global; 2020.
32. Silvestre-Roig C, Fridlender ZG, Glogauer M, Scapini P. Neutrophil Diversity in Health
and Disease. Trends Immunol 2019; 40: 565-583.
33. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Innate antiviral responses by
means of TLR7-mediated recognition of single-stranded RNA. Science 2004; 303:
1529-1531.
34. Moreno-Eutimio MA, Lopez-Macias C, Pastelin-Palacios R. Bioinformatic analysis and
identification of single-stranded RNA sequences recognized by TLR7/8 in the SARSCoV-2, SARS-CoV, and MERS-CoV genomes. Microbes Infect 2020; 22: 226-229.
35. Hattermann K, Picard S, Borgeat M, Leclerc P, Pouliot M, Borgeat P. The Toll-like
receptor 7/8-ligand resiquimod (R-848) primes human neutrophils for leukotriene B4,
prostaglandin E2 and platelet-activating factor biosynthesis. FASEB J 2007; 21: 15751585.
36. Grommes J, Soehnlein O. Contribution of neutrophils to acute lung injury. Mol Med
2011; 17: 293-307.
37. Vogt KL, Summers C, Chilvers ER, Condliffe AM. Priming and de-priming of neutrophil
responses in vitro and in vivo. Eur J Clin Invest 2018; 48 Suppl 2: e12967.
38. Hung IF, Lung KC, Tso EY, Liu R, Chung TW, Chu MY, Ng YY, Lo J, Chan J, Tam
AR, Shum HP, Chan V, Wu AK, Sin KM, Leung WS, Law WL, Lung DC, Sin S,
Yeung P, Yip CC, Zhang RR, Fung AY, Yan EY, Leung KH, Ip JD, Chu AW, Chan
WM, Ng AC, Lee R, Fung K, Yeung A, Wu TC, Chan JW, Yan WW, Chan WM,
Chan JF, Lie AK, Tsang OT, Cheng VC, Que TL, Lau CS, Chan KH, To KK, Yuen
KY. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the
treatment of patients admitted to hospital with COVID-19: an open-label, randomised,
phase 2 trial. Lancet 2020; 395: 1695-1704.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.15.20195305; this version posted January 28, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

39. Lucas C, Wong P, Klein J, Castro TBR, Silva J, Sundaram M, Ellingson MK, Mao T, Oh
JE, Israelow B, Takahashi T, Tokuyama M, Lu P, Venkataraman A, Park A, Mohanty
S, Wang H, Wyllie AL, Vogels CBF, Earnest R, Lapidus S, Ott IM, Moore AJ,
Muenker MC, Fournier JB, Campbell M, Odio CD, Casanovas-Massana A, Yale IT,
Herbst R, Shaw AC, Medzhitov R, Schulz WL, Grubaugh ND, Dela Cruz C,
Farhadian S, Ko AI, Omer SB, Iwasaki A. Longitudinal analyses reveal
immunological misfiring in severe COVID-19. Nature 2020; 584: 463-469.
40. Wu D, Sanin DE, Everts B, Chen Q, Qiu J, Buck MD, Patterson A, Smith AM, Chang
CH, Liu Z, Artyomov MN, Pearce EL, Cella M, Pearce EJ. Type 1 Interferons Induce
Changes in Core Metabolism that Are Critical for Immune Function. Immunity 2016;
44: 1325-1336.
41. Quah P, Li A, Phua J. Mortality rates of patients with COVID-19 in the intensive care
unit: a systematic review of the emerging literature. Crit Care 2020; 24: 285.
42. Mann ER, Menon M, Knight SB, Konkel JE, Jagger C, Shaw TN, Krishnan S, Rattray M,
Ustianowski A, Bakerly ND, Dark P, Lord G, Simpson A, Felton T, Ho LP, TRC NR,
Feldmann M, Circo, Grainger JR, Hussell T. Longitudinal immune profiling reveals
key myeloid signatures associated with COVID-19. Sci Immunol 2020; 5.
43. Silvin A, Chapuis N, Dunsmore G, Goubet AG, Dubuisson A, Derosa L, Almire C,
Henon C, Kosmider O, Droin N, Rameau P, Catelain C, Alfaro A, Dussiau C,
Friedrich C, Sourdeau E, Marin N, Szwebel TA, Cantin D, Mouthon L, Borderie D,
Deloger M, Bredel D, Mouraud S, Drubay D, Andrieu M, Lhonneur AS, Saada V,
Stoclin A, Willekens C, Pommeret F, Griscelli F, Ng LG, Zhang Z, Bost P, Amit I,
Barlesi F, Marabelle A, Pene F, Gachot B, Andre F, Zitvogel L, Ginhoux F, Fontenay
M, Solary E. Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate
Severe from Mild COVID-19. Cell 2020.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.15.20195305; this version posted January 28, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

44. Dorward DA, Russell CD, Um IH, Elshani M, Armstrong SD, Penrice-Randal R, Millar
T, Lerpiniere CE, Tagliavini G, Hartley CS, Randall NP, Gachanja NN, Potey PM,
Anderson AM, Campbell VL, Duguid AJ, Al Qsous W, BouHaidar R, Baillie JK,
Dhaliwal K, Wallace WA, Bellamy CO, Prost S, Smith C, Hiscox JA, Harrison DJ,
Lucas CD, . Tissue-specific tolerance in fatal Covid-19. medRxiv 2020.
45. Pufnock JS, Cigal M, Rolczynski LS, Andersen-Nissen E, Wolfl M, McElrath MJ,
Greenberg PD. Priming CD8+ T cells with dendritic cells matured using TLR4 and
TLR7/8 ligands together enhances generation of CD8+ T cells retaining CD28. Blood
2011; 117: 6542-6551.
46. Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, Moller R, Jordan TX,
Oishi K, Panis M, Sachs D, Wang TT, Schwartz RE, Lim JK, Albrecht RA, tenOever
BR. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19.
Cell 2020; 181: 1036-1045 e1039.
47. Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, Rawlings SA,
Sutherland A, Premkumar L, Jadi RS, Marrama D, de Silva AM, Frazier A, Carlin
AF, Greenbaum JA, Peters B, Krammer F, Smith DM, Crotty S, Sette A. Targets of T
Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease
and Unexposed Individuals. Cell 2020; 181: 1489-1501 e1415.
48. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, Wang T, Zhang X, Chen H, Yu H,
Zhang X, Zhang M, Wu S, Song J, Chen T, Han M, Li S, Luo X, Zhao J, Ning Q.
Clinical and immunological features of severe and moderate coronavirus disease
2019. J Clin Invest 2020; 130: 2620-2629.
49. Li CK, Wu H, Yan H, Ma S, Wang L, Zhang M, Tang X, Temperton NJ, Weiss RA,
Brenchley JM, Douek DC, Mongkolsapaya J, Tran BH, Lin CL, Screaton GR, Hou

medRxiv preprint doi: https://doi.org/10.1101/2020.09.15.20195305; this version posted January 28, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

JL, McMichael AJ, Xu XN. T cell responses to whole SARS coronavirus in humans.
J Immunol 2008; 181: 5490-5500.
50. Liu L, Wei Q, Lin Q, Fang J, Wang H, Kwok H, Tang H, Nishiura K, Peng J, Tan Z, Wu
T, Cheung KW, Chan KH, Alvarez X, Qin C, Lackner A, Perlman S, Yuen KY, Chen
Z. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses
during acute SARS-CoV infection. JCI Insight 2019; 4.
51. Sadiku P, Willson JA, Ryan EM, Sammut D, Coelho P, Watts ER, Grecian R, Young JM,
Bewley M, Arienti S, Mirchandani AS, Sanchez Garcia MA, Morrison T, Zhang A,
Reyes L, Griessler T, Jheeta P, Paterson GG, Graham CJ, Thomson JP, Baillie K,
Thompson AAR, Morgan JM, Acosta-Sanchez A, Darde VM, Duran J, Guinovart JJ,
Rodriguez-Blanco G, Von Kriegsheim A, Meehan RR, Mazzone M, Dockrell DH,
Ghesquiere B, Carmeliet P, Whyte MKB, Walmsley SR. Neutrophils Fuel Effective
Immune Responses through Gluconeogenesis and Glycogenesis. Cell Metab 2020.
52. McBrayer SK, Mayers JR, DiNatale GJ, Shi DD, Khanal J, Chakraborty AA, Sarosiek
KA, Briggs KJ, Robbins AK, Sewastianik T, Shareef SJ, Olenchock BA, Parker SJ,
Tateishi K, Spinelli JB, Islam M, Haigis MC, Looper RE, Ligon KL, Bernstein BE,
Carrasco RD, Cahill DP, Asara JM, Metallo CM, Yennawar NH, Vander Heiden MG,
Kaelin WG, Jr. Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate
Biosynthesis and Redox Homeostasis in Glioma. Cell 2018; 175: 101-116 e125.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.15.20195305; this version posted January 28, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

Table 1
Antibody

Clone

Catalogue
number

Fluorophore

Source

Concentration

CD16

eBioCB16

11-0168-42

FITC

Ebioscience

1:100

CD63

H5C6

353004

PE

Biolegend

1:100

CD10

K036C2

312214

PE-Cy7

Biolegend

1:100

CD66b

G10F5

305114

AF700

Biolegend

1:100

CD62L

DREG-56

304814

APC-Cy7

Biolegend

1:100

CD11b

M1/70

101243

BV785

Biolegend

1:400

CD49d

9F10

304322

BV421

Biolegend

1:100

CD41

HIP8

303729

BV421

Biolegend

1:100

CD18

TS1/18

302117

PE-Cy7

Biolegend

1:100

Table 1. List of antibodies used for multi-panel flow cytometry and microscopy. Detailed
list of all antibodies used for flow cytometry and microscopy staining. Refer to the
corresponding method details section for further information.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.15.20195305; this version posted January 28, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

Figure 1

FSC-H

Singlets

FSC-A

SSC-A

SSC-A

Live

Cells

Zombie Aqua Fixable
Viability

CD49d-

CD66b

CD16+

CD16-

SSC-A

SSC-A

SSC-A

CD66b+

SSC-A

SSC-A

SSC-A

FSC-A

CD49d

CD16

FMO

Figure 1. Representative plots of the gating strategy to analyse neutrophil populations.
Strategy shown in the direction of the arrows. Cells were gated for singlets on a forward scatter
height (FSC-H) vs. forward scatter area (FSC-A) plot. Singlets were then gated for cells on a

medRxiv preprint doi: https://doi.org/10.1101/2020.09.15.20195305; this version posted January 28, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

side scatter area (SSC-A) vs. FSC- plot, with non-viable cells excluded according to SSC-A
vs. Zombie Aqua Fixable Viability Dye parameter. Viable single cells were gated for CD66b+
cells to identify neutrophils and eosinophils excluded according to SSC-A vs. CD49d, with
fluorescence minus one (FMO) controls used to set gates. CD66b+CD49d- cells (neutrophils)
were gated for mature (CD16+) and immature (CD16-) neutrophils, with FMO controls used
to set gate.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.15.20195305; this version posted January 28, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

Table 2
Window

m/z

Isolation
window

Window

m/z

Isolation
window

1

383.375

66.8

24

670.5

14.5

2

423

13.5

25

684

13.5

3

435

11.5

26

697

13.5

4

446.5

12.5

27

710.5

14.5

5

458

11.5

28

725.5

16.5

6

469

11.5

29

741

15.5

7

480

11.5

30

756.5

16.5

8

490.5

10.5

31

773.5

18.5

9

501

11.5

32

791

17.5

10

512

11.5

33

808.5

18.5

11

523

11.5

34

827

19.5

12

533.5

10.5

35

846.5

20.5

13

544

11.5

36

866.5

20.5

14

554.5

10.5

37

887.5

22.5

15

565

11.5

38

910.5

24.5

16

575.5

10.5

39

935.5

26.5

17

586

11.5

40

962.5

28.5

18

597.5

12.5

41

992

31.5

19

609.5

12.5

42

1025

35.5

20

621.5

12.5

43

1063

41.5

21

633

11.5

44

1108.5

50.5

22

645

13.5

45

1391.625

516.8

23

657.5

12.5

Table 2. Inclusion list. Mass spectrometry isolation windows for data independent
acquisition analysis. Refer to the corresponding method details section for further
information.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.15.20195305; this version posted January 28, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

Table 3

Characteristic
Demographics
Age ‚Äì yr
Female sex ‚Äì no. (%)
Body-mass index ‚Äì kg/m2
Clinical Data
Cause of ARDS
Pulmonary ‚Äì no. (%)
Extra-pulmonary
APACHE II Score‚à•
Functional Comorbidity Index¬∂
Lowest SpO2 in 6 hrs prior to ICU
admission
Organ Injury and Support
Invasive mechanical ventilation
‚Äì no. (%)
Renal replacement therapy ‚Äì
no. (%)
Vasopressors ‚Äì no. (%)
ARDS Therapy‚Ä°
Peak pressure (cmH2O)
PEEP (cmH2O)
Tidal volume (ml)
Respiratory rate (breaths/min)
Medications
Lopinavir-Ritonavir ‚Äì no. (%)
Hydroxychloroquine ‚Äì no. (%)
Dexamethasone ‚Äì no. (%)

Non-COVID19 ARDS
(n = 7)

COVID-19
ARDS
(n = 12)

Moderate
COVID-19
(n = 3)

48.7¬±9.3
5 (71.4)
27.7¬±2.9

59.0¬±14.5
3 (25.0)
33.1¬±8.5

85.7¬±5.7
2 (66.7)
19.9¬±3.3

5 (71.4)
2 (28.6)
18.1¬±5.4

12 (100.0)
0 (0.0)
14.8¬±3.9

1.4¬±0.8

1¬±0.7

89.4¬±6.0

77¬±21

7 (100.0)

8 (66.7)

1

0

7 (100.0)

4 (33.3)

25.0¬±7.2
7.9¬±3.2
366.0¬±59.5
28.12¬±2.3

24¬±6
10¬±4
402¬±63
23.1¬±3.8

0 (0.0)
0 (0.0)
0 (0.0)

3 (25.0)
2 (16.7)
9 (75.0)

0 (0.0)
0 (0.0)
0 (0.0)

Table 3. Characteristics of study groups. For disease groups, all measurements were taken
at the time of trial sample unless otherwise specified. Plus-minus values are means ¬± SD. ‚Ä° For
COVID-19 ARDS group, data provided for 9 patients that were receiving invasive mechanical
ventilation (n=8) or non-invasive ventilation (n=1) at the time of the sample. The 3 other
patients were receiving high flow nasal oxygen at the time of the sample, so these
measurements were not available. Acute physiology and chronic health evaluation (APACHE

medRxiv preprint doi: https://doi.org/10.1101/2020.09.15.20195305; this version posted January 28, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

II) score, ¬∂ Functional Comorbidity Index (FCI), arterial partial pressure of oxygen (PaO 2),
peripheral oxygen saturation (SpO2), positive end-expiratory pressure (PEEP).

medRxiv preprint doi: https://doi.org/10.1101/2020.09.15.20195305; this version posted January 28, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

Figure 2
A
PATIENT SELECTION
Non-COVID-19

EXPERIMENTAL STRATEGY

COVID-19
Flow cytometry
FACS
ELISA

LDN

Immunostaining

PBMC
Flow cytometry

plasma

Proteome
PMN

HC

NA

MC

Metabolome
In vitro assays

density
separation

CA

B

C
CA

NA

PMN

PBMC

SSC

CD16

HC

FSC

CD10

E

D

2

1

4

2

NA

MC

NA

CA

G

6
4
2
0

0

0

MC

NA

CA

MC

CA

H
6

50
LDN
(% of total neutrophils)

Neutrophils
(x106 cells/ml)

8
CD63
(MFI fold change from HC)

CD66b
(MFI fold change from HC)

CD62L
(MFI fold change from HC)

F
6

3

4

2

0
HC

NA

MC

CA

Immature

40

Mature

30
20
10
0
HC

NA

MC

CA

CD

Figure 2. Circulating neutrophil populations are expanded in COVID-19 and nonCOVID-19 ARDS. (A) Patient classification (healthy control, HC, non-COVID-19 ARDS,
NA, moderate COVID-19, MC, and COVID-19 ARDS, CA), neutrophil isolation, and
workflow depicted. (B) Representative side scatter (SSC) vs. forward scatter (FSC) plots of
stained whole blood from HC, NA and CA displaying lymphocyte (green), monocyte (pink),

medRxiv preprint doi: https://doi.org/10.1101/2020.09.15.20195305; this version posted January 28, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

mature (CD16+, orange) and immature (CD16-, blue) neutrophil populations. (C)
Representative CD16 vs. CD10 dot plots of stained polymorphonuclear (PMN) and peripheral
blood mononuclear cell (PBMC) layers isolated by Percoll gradients from HC (grey), NA
(blue) or CA (pink) patients, with quadrant2 (Q2) delimiting the CD16+CD10+ (mature
neutrophils) area. (D-F) Surface expression of neutrophil activation markers expressed as a
fold change of geometric mean fluorescence intensity (MFI) from normal density neutrophils
(NDN) respective to the disease state as determined by flow cytometry analysis of mature NDN
(CD66b+CD16+, open bars), mature low density neutrophils (LDN) (CD66b+CD16+,
horizontal striped bars) and immature LDN (CD66b+CD16-, vertical striped bars) from NA (n
= 5), MC (n = 3), or COVID-19 (n = 11; open circles, dexamethasone treated patients) patients.
Data are mean ¬± SD. *p < 0.05, determined by repeated two-way ANOVA and Sidak‚Äôs post
hoc-testing. (G) Total neutrophil counts of HC (n = 8), NA (n = 5), MC (n=3) and CA (n = 11)
performed by haemocytometer and differential cell count established by flow cytometry. Data
are mean ¬± SD. ****p < 0.0001, determined by one-way ANOVA and Holm-Sidak‚Äôs post hoctesting. (H) The proportion of mature (CD66b+CD16+CD10+, grey bars) and immature
(CD66b+CD16-CD10-, white bars) LDN isolated from patient cohorts as described in (G),
with CA patients treated with dexamethasone as CD, were measured by flow cytometry. Data
are mean ¬± SD. *p < 0.05, ***p < 0.001, determined by repeated measures two-way ANOVA
and Sidak‚Äôs post hoc-testing.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.15.20195305; this version posted January 28, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

Figure 3

Figure 3. Circulating neutrophils preserve global cellular processes in both COVID-19
and non-COVID-19 ARDS. (A) Number of proteins identified by proteomic analysis in

medRxiv preprint doi: https://doi.org/10.1101/2020.09.15.20195305; this version posted January 28, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

normal density neutrophils (NDN) isolated from healthy controls (HC, n = 4), non-COVID-19
ARDS patients (NA, n = 6) and COVID-19 ARDS patients (CA, n = 7), with open circles
depicting the data corresponding to dexamethasone-treated patients. Refer to methods section
for details. Data are mean ¬± SD. (B-C) Total protein content, protein content of mitochondria
(GO:0005739), ribosomes (Kyoto Encyclopaedia of Genes and Genomes annotation 03010),
nuclear envelope (GO:0005635) and cytoskeleton (GO:0005856) in the same samples
described in (A) determined by proteomic analysis. Data as mean ¬± SD. (D) Abundance of
components of the eIF4F translation initiation complex (figure adapted from Howden et al.
2019(49)) in the same samples described in (A) determined by proteomic analysis. Data as
mean ¬± SD. (E) Volcano plots reflecting the expression profile of transcription factors in the
samples from CA vs. HC, and NA vs. ARDS depicted in (A) after proteomic analysis. Proteins
were included with the annotation GO:0003700 (DNA binding transcription factor activity).
Horizontal dashed line indicates a P value = 0.05, outer vertical dashed lines indicate a fold
change = 2. P values calculated using Linear Models for Microarray data analysis. The DNA
binding transcription factor proteins TRIM22, STAT1 and NR3C1 are highlighted.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.15.20195305; this version posted January 28, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

Figure 4
A
NA vs HC
10

8

8

p value (-log10)

p value (-log10)

CA vs HC
10

6
4
2

6

p<0.05, fold change>2 ,
copies>200

4
2
0

0
-5

0

-5

5

B

0

5

NA/HC (log2)

CA/HC (log2)

GO term enrichment
analysis
Greater abundance
CA vs HC

204

213

106

Greater abundance
NA vs HC

Figure 4. Specific proteome remodelling in circulating neutrophils in response to COVID19 ARDS and ARDS. (A) Volcano plots obtained from proteomic survey of normal density

medRxiv preprint doi: https://doi.org/10.1101/2020.09.15.20195305; this version posted January 28, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

neutrophils (NDN) isolated from healthy controls (HC, n = 4), non-COVID-19 ARDS patients
(NA, n = 6) and COVID-19 ARDS patients (CA, n = 7). Refer to methods section for details.
Proteins with a P value <0.05 (horizontal dashed lines), fold change >2 (outer vertical dashed
lines) and a copy number >200 in at least one condition after Linear Models for Microarray
data analysis were considered as significantly different in the comparisons CA vs HC (left) and
NA vs HC (right). (B) GO term enrichment analysis for proteins significantly increased in
abundance in CA and NA patients vs HC. Venn diagram shows the numbers of proteins
uniquely increased in abundance in CA and NA and also the number of proteins shared between
these 2 groups. A selection of the top enriched GO terms and the corresponding proteins are
shown.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.15.20195305; this version posted January 28, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

Figure 5

A
F13A1

Fibrinogen beta

4√ó102
2√ó102

Copy number

Copy number

Copy number

8√ó102
6√ó102

1.5√ó104

2.0√ó103

1.5√ó103

1.0√ó103

5.0√ó102

1.5√ó103

Copy number

Fibrinogen alpha
1√ó103

1.0√ó103
5.0√ó102

Antithrombin-III

1.0√ó104

5.0√ó103

0
HC

NA

0.0

0.0

0.0

-2√ó102

HC

CA

NA

HC

CA

NA

HC

CA

NA

CA

B
Platelet Factor 4

5√ó104

3√ó104

Copy number

Copy number

4√ó104

2√ó104
1√ó104

Platelet Basic Protein

4√ó104
3√ó104
2√ó104
1√ó104
0

0
HC

NA

HC

CA

NA

CA

C
CA LDN

HC NDN
PI

PI

CD41

CD41

PI
CD41

PI
CD41

E

D
100

6000

30000

4000

20000

60
40

CD18 (MFI)

CD11b (MFI)

CD41+ (%)

80

2000

10000

20

HC

NA

MC

HC

CA

F
6

CD18
(MFI fold change from N-U)

CD11b
(MFI fold change from N-U)

0

0

0

4

2

0
H-U 0

0.1

1

[Dexamethasone] (¬µM)

2.5
2.0
1.5
1.0
0.5
0.0
H-U 0

0.1

1

[Dexamethasone] (¬µM)

NA

MC

CA

HC

NA

MC

CA

medRxiv preprint doi: https://doi.org/10.1101/2020.09.15.20195305; this version posted January 28, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

Figure 5. COVID-19 ARDS neutrophils form aggregates with platelets and activate
prothrombotic pathways. (A) Copy numbers of proteins that regulated fibrin clot formation
in normal density neutrophils (NDN) isolated from healthy controls (HC, n = 3-4), nonCOVID-19 ARDS (NA, n = 4-6), and COVID-19 ARDS (CA, n = 7, with open circles
depicting the data corresponding to dexamethasone-treated patients) patients determined by
proteomic analysis. For fibrinogen alpha, fibrinogen beta and antithrombin-III, data as mean ¬±
SD, *p < 0.05, determined by Kruskal-Wallis and Dunn‚Äôs post hoc-testing. For coagulation
factor XIII alpha chain (F13A), data as mean ¬± SD. (B) Copy numbers of proteins associated
with platelets in the same samples described in (A) determined by proteomic analysis. Data as
mean ¬± SD. (C) Representative confocal images from NDN obtained from a healthy donor and
LDN from a CA patient isolated by FACS and stained for propidium iodide (top left panel,
red) and CD41 (top right panel, green). Bright field image was used to delimit cell contour
(bottom left panel, grey scale). A composite image is shown in bottom right panel. Scale bar
corresponds to 5 ÔÅ≠m, 63x magnification. (D) Percentage of NDN (open bars), mature LDN
(horizontal striped bars) and immature LDN (vertical striped bars) isolated from HC (n = 6-7),
NA (n = 3-5), MC (n = 3) or CA patients (n = 8-11; open circles depict dexamethasone treated
patients) with surface expression of CD41. Data are median ¬± I.Q.R. *p < 0.05, ****p < 0.0001
vs. HC, determined be Kruskal-Wallis and Dunn‚Äôs post hoc-testing. (E) Surface expression of
CD11b and CD18 (Mac-1 complex) displayed as geometric mean fluorescence intensity (MFI)
determined by flow cytometry analysis of neutrophil populations described in (D). Data are
mean ¬± SD. **p < 0.01, ***p < 0.001, determined by repeated measures two-way ANOVA
and Sidak‚Äôs post hoc-testing; *p < 0.05, **p < 0.01 vs. HC, determined be one-way ANOVA
and Holm-Sidak‚Äôs post hoc-testing. (F) Surface expression of CD11b and CD18 (Mac-1
complex) expressed as a fold change of MFI of HC NDN cultured under untreated normoxic
conditions (N-U) determined by flow cytometry analysis of HC NDN cultures in hypoxia under

medRxiv preprint doi: https://doi.org/10.1101/2020.09.15.20195305; this version posted January 28, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

untreated conditions (H-U) or with varying doses of dexamethasone for 3 h and follow-up
treatment with resiquimod for 1 h. Data are mean ¬± SD (n = 3-5). *p < 0.05, determined by
repeated measures one-way ANOVA and Holm-Sidak‚Äôs post hoc-testing.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.15.20195305; this version posted January 28, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

Figure 6

HC

NA

21.6% of protein mass
‚Ä¢ 11.0% primary
‚Ä¢ 9.5% secondary
‚Ä¢ 1.1% tertiary

B

CA

21.1% of protein mass
‚Ä¢ 12.2% primary
‚Ä¢ 7.7% secondary
‚Ä¢ 1.2% tertiary

19.7% of protein mass
‚Ä¢ 11.1% primary
‚Ä¢ 7.0% secondary
‚Ä¢ 1.5% tertiary

Granule proteins (ug/million cells)

A

Primary
Secondary
Tertiary

*

20

Membrane

10
5
1.0
0.5
0.0
HC

E

2√ó107
1√ó107

HC

NA

NA

1√ó107

CA

I

J

PRTN3

1√ó107

1√ó107

4√ó106
2√ó106

NA

CA

CA

NA

4√ó107
2√ó107
0

HC

NA

HC

CA

3000

CA

2000

1.0√ó107

1000

1500
1000

5.0√ó106

CA

NA

2500

2000

500
0

0.0
HC

6√ó107

K

1.5√ó107

0
HC

2√ó107

2.0√ó107

6√ó106

0

NA

LCN2

CAMP

Copy number

Copy number

2√ó107

4√ó107

0
HC

8√ó106
Copy number

2√ó107

6√ó107

0
HC

CA

H
3√ó107

3√ó107

0

0

LYZ
8√ó107

Copy number

2√ó107

3√ó107

CA

G

Elastase
8√ó107

4√ó107

Copy number

4√ó107

F
Lactoferrin

MPO

Copy number

Copy number

Copy number

4√ó107

NA

CD66b (MFI)

D
CTSG

6√ó107

CD63 (MFI)

C

Content

*
15

HC

NA

0
HC NA MC CA

CA

HC NA MC CA

40
30
20
10
0
NA

CA

0.06
5
4
3
2
1

0.5

0.0
CA

10

5

0

2.0
1.5
1.0
0.5
0.0

CD

CA

NA

CA

CA

CD

CA

Elastase (Fold change from CA)

Lactoferrin (Fold change from CA)

2.0
1.5
1.0
0.5
0.0

CD

N

O

0.5

0.0

2

1

0
H-U

H-R

2

1

0
H-U

H-R

8

5
MPO
(fold change from N-U)

1.0

CD66b
(MFI fold change from N-U)

CD63
(MFI fold change from N-U)

CD62L
(MFI fold change from N-U)

3

3

1.5

Lactoferrin
(fold change from N-U)

MPO (Fold change from CA)

M

1.0

15

0
NA

1.5

Elastase (Fold change from HC)

50

Lactoferrin (Fold change from HC)

MPO (Fold change from HC)

L

4
3
2
1
0

H-U

H-R

6
4
2
0

H-U

H-R

H-U

H-R

Figure 6. Enhanced circulating neutrophil degranulation in COVID-19. (A) Pie charts
show distribution of protein mass for proteins integrating primary, secondary or tertiary

medRxiv preprint doi: https://doi.org/10.1101/2020.09.15.20195305; this version posted January 28, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

granules in healthy control (HC, n = 4), non-COVID-19 ARDS (NA, n = 6) and COVID-19
ARDS (CA, n = 7) patients. Data obtained from proteomic analysis of normal density
neutrophils (NDN). (B) Membrane (grey bars) and content (white bars) granule cargo protein
abundance in NDN isolated from the samples described in (A). Data are mean ¬± SD. *p < 0.05,
determined by two-way ANOVA and Tukey‚Äôs post hoc-testing. (C-J) Copy numbers of granule
proteins in the samples described in (A, open circles depict dexamethasone-treated patients).
For (C-E), data are mean ¬± SD. For (F-J), data are mean ¬± SD. **p < 0.01, determined be oneway ANOVA and Holm-Sidak‚Äôs post hoc-testing. (K) Surface expression of CD63 and CD66b
displayed as mean fluorescence intensity (MFI) determined by flow cytometry analysis of
NDN isolated from HC (n = 7), NA (n = 5), moderate COVID-19 (MC, n = 3) and CA (n = 12,
open circles depict dexamethasone-treated patients) patients. For CD63, data are mean ¬± SD.
**p < 0.01, ***p < 0.001, determined be one-way ANOVA and Holm-Sidak‚Äôs post hoc-testing.
For CD66b, data are median ¬± I.Q.R. *p < 0.05, **p < 0.01, determined by Kruskal-Wallis and
Dunn‚Äôs post hoc-testing. (L) Granule protein levels in serum of NA (n = 6), and CA (n = 3)
patients measured by ELISA represented as a fold change from HC. For MPO, data are median
¬± I.Q.R. *p < 0.05, determined by Mann-Whitney test. For elastase, data are mean ¬± SD. *p <
0.05, determined by unpaired t-test. (M) Granule protein levels in serum of CA (n = 3), and
COVID-19 ARDS dexamethasone-treated (CD, n = 5) patients measured by ELISA
represented as a fold change from CA. For MPO and lactoferrin, data are mean ¬± SD. For
elastase, data are median ¬± I.Q.R. (N) Surface expression of activation markers expressed as a
fold change of MFI of HC NDN under untreated normoxic conditions (N-U) determined by
flow cytometry analysis of HC NDN cultures in hypoxia under untreated conditions (H-U) or
with resiquimod (H-R) for 1 h. Data are mean ¬± SD. *p < 0.05, **p < 0.01, determined by
paired one-tailed t-test. (O) Granule protein levels measured in H-U and H-R HC NDN culture

medRxiv preprint doi: https://doi.org/10.1101/2020.09.15.20195305; this version posted January 28, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

supernatants at 4 h by ELISA expressed as a fold change of a N-U group. Data are mean ¬± SD.
*p < 0.05, determined by paired t-test.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.15.20195305; this version posted January 28, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

Figure 7

4√ó104
2√ó104

2.0√ó105

1.5√ó105

1.5√ó105

Copy number

Copy number

Copy number

6√ó104

1.0√ó105
5.0√ó104

0

0.0

HC

C

NA

CA

HC

NA

EIF2AK
1√ó105
8√ó104

1.0√ó105
5.0√ó104

6√ó104
4√ó104
2√ó104
0

0.0

CA

HC

NA

D

MX2

MX1
6√ó105

B

OAS3

OAS2
2.0√ó105

HC

CA

Copy number

4

Copy number

Copy number

Copy number

5√ó104
4√ó104

1.0√ó105

5.0√ó10

PSMB10

1.5√ó105

1.5√ó105

2√ó105

CA

PSMB9

PSMB8

1.5√ó105

4√ó105

NA

1.0√ó105

5.0√ó104

Copy number

OAS1
8√ó104

Copy number

A

1.0√ó105

5.0√ó104

3√ó104
2√ó104
1√ó104

0
HC

NA

0.0

CA

HC

NA

0.0

0.0

CA

HC

NA

0
HC

CA

NA

CA

HC

NA

CA

E
p value (-log10)

5
OAS3

4

TAP2

3

TAP1
HLA-C

2

IFIT5

1
0

-5

-4

-3

-2

-1

0

1

2

3

4

5

CA/HC (log2)

p value (-log10)

5
4
3
2

IFIT5
OAS3

1

TAP2
TAP1

HLA-C

0

-5

-4

-3

-2

-1

0

1

2

3

4

5

NA/HC (log2)

0

3√ó104
2√ó104
1√ó104

NA

CA

2√ó105

1√ó105

2.0√ó105

1.0√ó105

5.0√ó104

1.5√ó105
1.0√ó105
5.0√ó104

0.0

0

0
HC

HLA-C
2.5√ó105

Copy number

2√ó104

3√ó10

1.5√ó105

5

Copy number

4√ó104

HLA-B

HLA-A

4√ó104

Copy number

Copy number

G

TAP2

TAP1

6√ó104

Copy number

F

HC

NA

CA

HC

NA

CA

0.0

HC

NA

CA

HC

NA

CA

Figure 7. Activation of neutrophil type I interferon signalling pathways and antigen
presentation in COVID-19. (A) Copy numbers of OAS proteins involved in type I IFN

medRxiv preprint doi: https://doi.org/10.1101/2020.09.15.20195305; this version posted January 28, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

signalling and anti-viral responses in normal density neutrophils (NDN) isolated from healthy
controls (HC, n = 4), non-COVID-19 ARDS (NA, n = 6) and COVID-19 ARDS (CA, n = 7,
open circles depicting dexamethasone-treated patients) patients determined by proteomic
analysis. Data are mean ¬± SD. *p < 0.05, **p < 0.01, ***p < 0.001, determined by one-way
ANOVA and Holm-Sidak‚Äôs post hoc-testing. (B) Copy numbers of EIF2AK in the same
samples described in (A). Data are mean ¬± SD. *p < 0.05, determined by Kruskal-Wallis and
Dunn‚Äôs post hoc-testing. (C) Copy numbers of Mx proteins in the same samples described in
(A). Data are mean ¬± SD. *p < 0.05, **p < 0.01, determined by one-way ANOVA and HolmSidak‚Äôs post hoc-testing. (D) Copy numbers of PSMB proteins in the same samples described
in (A). Data are mean ¬± SD. (E) Volcano plots (left) obtained from proteomic survey of normal
density neutrophils (NDN) isolated from the samples described in (A) including a selection of
proteins implicated in antigen processing and presentation and interferon signalling
(GO:0002376) highlighted in red and with some of them labelled as illustrative examples.
Refer to methods section for details. Proteins with a P value <0.05 (horizontal dashed lines),
fold change >2 (outer vertical dashed lines) and a copy number >200 in at least one condition
after Linear Models for Microarray data analysis were considered as significantly different in
the comparisons CA vs HC (top) and NA vs HC (bottom). Table (right) includes a selection of
proteins from the samples described in (A) involved in antigen processing and presentation or
interferon signalling which significantly change in abundance in CA vs. HC (>2 fold change,
p<0.05). Proteins highlighted in red show a COVID-19 specific signature and did not
significantly change in non-COVID-19 ARDS alone. Mean copy numbers are shown. (F) Copy
numbers of Transporter Associated with Antigen Processing (TAP) proteins in the same
samples described in (A). For TAP-1, data are mean ¬± SD. **p < 0.01, determined by one-way
ANOVA and Holm-Sidak‚Äôs post hoc-testing. For TAP-2, data are mean ¬± SD. *p < 0.05, **p
< 0.01, determined by Kruskal-Wallis and Dunn‚Äôs post hoc-testing. (G) Copy numbers of

medRxiv preprint doi: https://doi.org/10.1101/2020.09.15.20195305; this version posted January 28, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

Major Histocompatibility Complex molecules in the same samples described in (A). Data are
mean ¬± SD. *p < 0.05, **p < 0.01 determined by one-way ANOVA and Holm-Sidak‚Äôs post
hoc-testing.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.15.20195305; this version posted January 28, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

Figure 8
Glycolysis

A
RES

G

2DG

80

100
ECAR (mpH/min)

Glyc. Cap.

150

Glycolysis

100

UT
RES

50

RES + IFN

0
0

50

100

150

Time (minutes)

C
TCA Intermediaries
(RI fold change from N-U)

lactate
(RI fold change from N-U)

1.1
1.0
0.9
0.8
0.7
0.6
H-U

0
IFN

-

-

RES

-

+

0

1.0

0.5

+
+

0.0

H-I

-

-

-

+

+
+

1.6
1.4
1.2
1.0
0.8

e
te ate
ate
lat
ra
cit utar ma ccin
u
gl
s
o
t
ke
ha
alp

4√ó108
2√ó108

Glutamate
(AU)

Glutamine
(AU)

20

D

6√ó108

6√ó107
4√ó107

8√ó107
7√ó107
6√ó107
5√ó107
4√ó107
3√ó107
8√ó106
6√ó106

H-U

H-I

0.05

0.06

4√ó106
2√ó106
0

2√ó107
0

m+1

m+2

G

1√ó108

Lactate
Abundance (AU)

8√ó107
6√ó107
4√ó107
2√ó107

m+T

m+0

H

1.5√ó109

1.0√ó109

5.0√ó108

HC

NA

CA

m+2

m+T

I

109

108

107

0.0

0

m+1

1010

TCA Intermediaries
(AU)

m+0

Glucose
Abundance (AU)

50

1.5

E 8√ó108

F

40

Glutamate
(RI fold change from N-U)

B

60

Glutamate
Abundance (AU)

ECAR (mpH/min)

OA

Glycolytic Capacity

HC

NA

CA

2.0√ó109
1.5√ó109
1.0√ó109
5.0√ó108
0.0

te
ra
cit

te
ra
ta
glu
o
t
ke
ha
alp

te
ala
m

te
te
ta
ina
ce
cc
loa
su
a
ox

HC

NA

CA

Figure 8. Metabolic rewiring of COVID-19 ARDS neutrophils correspond to changes in
neutrophil metabolism in response to type I interferon (A) Glycolytic behaviour as
determined by extracellular flux analysis during the glycolysis stress test in hypoxia (3% O 2).
HC NDN were cultured in hypoxia (1% O2) with IFNŒ±/ IFNŒ≤ (IFN) or without (UT) for 3 h
05/01/2021

before sequential injections of resiquimod (RES), glucose (G), oligomycin A (OA) and 2deoxyglucose (2DG) and extracellular acidification rate (ECAR) determined and used to

medRxiv preprint doi: https://doi.org/10.1101/2020.09.15.20195305; this version posted January 28, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

calculate glycolysis and glycolytic capacity (Glyc. Cap.). Data are mean ¬± SD (n = 5, individual
data points represent mean of at least two technical replicates from individual donors). *p <
0.05, **p < 0.01, determined by repeated measures one ANOVA and Tukey‚Äôs post hoc-testing.
(B-D) Lactate (B), TCA intermediaries (C) and glutamate (D) abundance in neutrophils
cultured in hypoxia for 4 hours with IFNŒ±/ IFNŒ≤ (H-I/spotted bars) or without (H-U/open bars)
relative to normoxic untreated control cells and determined by p-HILIC LCMS. Data are mean
¬± SD (n = 4, individual data points represent individual donors). *p < 0.05, **p < 0.01
determined by ratio paired t-test. (E) Glutamine and glutamate isotopomer abundance
(Arbitrary Units, AU) as determined by p-HILIC LCMS in neutrophils cultured as in (B-D) in
the presence of 2 mM U-13C5 glutamine for 4 h. Individual data points represent individual
donors, n = 4. Data are mean ¬± SD. *p<0.05, determined by paired t-test. (F-I) D-glucose (F),
lactate (G), TCA intermediary (H) and glutamate (I) abundance in normal density neutrophils
(NDN) isolated from healthy controls (HC/open bars, n= 5) and patients with non-COVID-19
ARDS (NA/spotted bars, n = 6) or COVID-19 ARDS (CA/diagonal striped bars, n = 9 with 6
patients receiving dexamethasone treatment indicated by open symbols) was determined by IP
LCMS (arbitrary units, AU). Data are mean ¬± SD (F, G and I) or median ¬± I.Q.R (H). HC, NA
and CA were compared by student‚Äôs t-test (F, G and I) or Mann-Whitney (H) where *p < 0.05
and **p < 0.01.

